198 related articles for article (PubMed ID: 30621625)
1. Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells.
Qiu X; Wang W; Li B; Cheng B; Lin K; Bai J; Li H; Yang G
BMC Cancer; 2019 Jan; 19(1):27. PubMed ID: 30621625
[TBL] [Abstract][Full Text] [Related]
2. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
[TBL] [Abstract][Full Text] [Related]
3. Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31.
Zhang Q; Padi SK; Tindall DJ; Guo B
Cell Death Dis; 2014 Oct; 5(10):e1486. PubMed ID: 25341040
[TBL] [Abstract][Full Text] [Related]
4. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.
Ling Z; Wang X; Tao T; Zhang L; Guan H; You Z; Lu K; Zhang G; Chen S; Wu J; Qian J; Liu H; Xu B; Chen M
J Exp Clin Cancer Res; 2017 Nov; 36(1):159. PubMed ID: 29141691
[TBL] [Abstract][Full Text] [Related]
5. MiR-129-5p promotes docetaxel resistance in prostate cancer by down-regulating CAMK2N1 expression.
Wu C; Miao C; Tang Q; Zhou X; Xi P; Chang P; Hua L; Ni H
J Cell Mol Med; 2020 Feb; 24(3):2098-2108. PubMed ID: 31876385
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of anticancer activity of docetaxel by combination with Fuzheng Yiliu decoction in a mouse model of castration-resistant prostate cancer.
Fu W; Hong Z; You X; Din J; Chen B; Zhao B; Yuan G; Li Q
Biomed Pharmacother; 2019 Oct; 118():109374. PubMed ID: 31545228
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-195 regulates docetaxel resistance by targeting clusterin in prostate cancer.
Ma X; Zou L; Li X; Chen Z; Lin Q; Wu X
Biomed Pharmacother; 2018 Mar; 99():445-450. PubMed ID: 29665645
[TBL] [Abstract][Full Text] [Related]
8. MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells.
Erdmann K; Kaulke K; Rieger C; Salomo K; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2249-61. PubMed ID: 27562865
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-144 Suppresses Prostate Cancer Growth and Metastasis by Targeting EZH2.
Sun XB; Chen YW; Yao QS; Chen XH; He M; Chen CB; Yang Y; Gong XX; Huang L
Technol Cancer Res Treat; 2021; 20():1533033821989817. PubMed ID: 33550923
[TBL] [Abstract][Full Text] [Related]
10. Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis.
Tao T; Chen M; Jiang R; Guan H; Huang Y; Su H; Hu Q; Han X; Xiao J
Oncol Rep; 2017 Mar; 37(3):1430-1436. PubMed ID: 28184935
[TBL] [Abstract][Full Text] [Related]
11. Acetyl-11-keto-β-boswellic acid suppresses docetaxel-resistant prostate cancer cells in vitro and in vivo by blocking Akt and Stat3 signaling, thus suppressing chemoresistant stem cell-like properties.
Liu YQ; Wang SK; Xu QQ; Yuan HQ; Guo YX; Wang Q; Kong F; Lin ZM; Sun DQ; Wang RM; Lou HX
Acta Pharmacol Sin; 2019 May; 40(5):689-698. PubMed ID: 30171201
[TBL] [Abstract][Full Text] [Related]
12. The long non-coding RNA PCSEAT exhibits an oncogenic property in prostate cancer and functions as a competing endogenous RNA that associates with EZH2.
Yang X; Wang L; Li R; Zhao Y; Gu Y; Liu S; Cheng T; Huang K; Yuan Y; Song D; Gao S
Biochem Biophys Res Commun; 2018 Jul; 502(2):262-268. PubMed ID: 29803673
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-223-3p regulates cell chemo-sensitivity by targeting FOXO3 in prostatic cancer.
Feng Q; He P; Wang Y
Gene; 2018 Jun; 658():152-158. PubMed ID: 29518547
[TBL] [Abstract][Full Text] [Related]
14. Reversal of docetaxel resistance in prostate cancer by Notch signaling inhibition.
Qiu S; Deng L; Bao Y; Jin K; Tu X; Li J; Liao X; Liu Z; Yang L; Wei Q
Anticancer Drugs; 2018 Oct; 29(9):871-879. PubMed ID: 29944470
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer.
Li X; Gera L; Zhang S; Chen Y; Lou L; Wilson LM; Xie ZR; Sautto G; Liu D; Danaher A; Mamouni K; Yang Y; Du Y; Fu H; Kucuk O; Osunkoya AO; Zhou J; Wu D
Theranostics; 2021; 11(14):6873-6890. PubMed ID: 34093859
[No Abstract] [Full Text] [Related]
16. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer.
Wu C; Jin X; Yang J; Yang Y; He Y; Ding L; Pan Y; Chen S; Jiang J; Huang H
Oncotarget; 2016 Jan; 7(3):3440-52. PubMed ID: 26657505
[TBL] [Abstract][Full Text] [Related]
17. Conditionally replicative adenovirus carrying shRNA targeting EZH2 inhibits prostate cancer growth and invasion.
Xu SG; Yu JJ; Shi Q; Niu Q; Guo Z; Guo BY; Zhou GC; Gu X; Wu YX
Oncol Rep; 2019 Jul; 42(1):273-282. PubMed ID: 31115564
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
Armstrong CM; Liu C; Lou W; Lombard AP; Evans CP; Gao AC
Prostate; 2017 Jun; 77(9):1020-1028. PubMed ID: 28485104
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-126 increases chemosensitivity in drug-resistant gastric cancer cells by targeting EZH2.
Wang P; Li Z; Liu H; Zhou D; Fu A; Zhang E
Biochem Biophys Res Commun; 2016 Oct; 479(1):91-6. PubMed ID: 27622325
[TBL] [Abstract][Full Text] [Related]
20. Aristeromycin and DZNeP cause growth inhibition of prostate cancer via induction of mir-26a.
Uchiyama N; Tanaka Y; Kawamoto T
Eur J Pharmacol; 2017 Oct; 812():138-146. PubMed ID: 28705714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
